No genetic alterations were found in SEC14L2 and SLC6A1 in HCC; however, SEC14L2 was altered in 1 (0.3%) of 366 patients, and SLC6A1 was altered in 5 (1.4%) of 366 patients with liver cancer in the cBioPortal database. This evidence concerns the gene SEC14L2 and hepatocellular carcinoma.